The Board of Directors of the Company at its meeting held today i.e. 29th May, 2026, which commenced at 04:00 P.M. and concluded at 05:30 P.M. have inter alia transacted the following business(es):(a) Adopted the Audited Financial Statements (both Standalone and Consolidated) of the Company for the financial year ended on 31st March, 2026.(b) Approved the Audited Financial Results (both Standalone and Consolidated) of the Company for the quarter and year ended on 31st March, 2026. (c) Approved re-appointment of Agrawal Tondon & Co. (FRN: 329088E) as Internal Auditor of the Company for the Financial Year 2026-27.(d) Based on the recommendation of the Nomination and Remuneration Committee and approval of the Audit Committee, the Board approved the re-appointment of Mr. Suresh Kumar Agrawal (DIN: 00520769) as Managing Director of the Company for a further period of three years w.e.f. 23rd November, 2026 subject to the approval of the shareholders.
MANAKSIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Manaksia Limited's Board adopted audited standalone and consolidated financial results for FY2026 (year ended 31 March 2026). Consolidated revenue grew 7.3% to Rs. 82,264 lakhs, but profit before tax declined 17% to Rs. 7,065 lakhs compared to Rs. 8,479 lakhs in FY2025, primarily due to lower EBITDA of Rs. 7,983 lakhs versus Rs. 10,848 lakhs previously. Standalone PAT also declined 9% to Rs. 5,292 lakhs. Statutory auditors S K Agrawal & Co issued unmodified opinions on both standalone and consolidated results with no qualifications. The Board reappointed Agrawal Tondon & Co as internal auditor for FY2026-27 and approved re-appointment of Mr. Suresh Kumar Agrawal (72) as Managing Director for a further 3-year term from 23 November 2026, subject to shareholder approval. Note: Mr. Varun Agrawal (MD's son) serves as Non-Executive Director, indicating a related party relationship.
The profit decline despite revenue growth suggests margin compression; shareholders should note the 26% drop in consolidated EBITDA. The MD reappointment maintains continuity but involves a related party (his son is also on the Board). The unmodified audit opinion with no going concern issues is a positive signal.